Patents by Inventor David Uehling

David Uehling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoindolinone aminopyrimidine compounds as inhibitors of NUAK kinases, compositions and uses thereof
    Patent number: 12643886
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: June 2, 2026
    Assignee: Ontario Institute for Cancer Research (OICR), The Governing Council of the University of Toronto, Sinai Health System
    Inventors: Rima Al-Awar, Liliana Attisano, Methvin Isaac, Yong Liu, David Smil, David Uehling, Jeff Wrana
  • ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF
    Publication number: 20250154140
    Abstract: The present application relates to isoquinoline compounds of Formula (I), to processes for their preparation and to compositions comprising them. More particularly, the present application relates to compound of Formula (I) that have activity as inhibitors of Bcl2-associated X protein (BAX) and/or Bcl-2 antagonist killer (BAK), and to their use in the treatment of diseases, disorders or conditions treatable by inhibiting BAX and/or BAK such as neurodegenerative diseases, disorders or conditions.
    Type: Application
    Filed: February 17, 2023
    Publication date: May 15, 2025
    Applicants: Sunnybrook Research Institute, Ontario Institute for Cancer Research (OICR)
    Inventors: David Andrews, Justin Kale, Justin Pogmore, Rima Al-Awar, Methvin Isaac, Gennady Poda, David Uehling, Tao Xin, Joshua Barry Cohen, Bridget McCarthy Cole
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 12264147
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: April 1, 2025
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Katheleen Stille
  • HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1)
    Publication number: 20240425479
    Abstract: The present application relates to halo-substituted aza-heteroaryl compounds of Formula (I): (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.
    Type: Application
    Filed: May 2, 2022
    Publication date: December 26, 2024
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Ahn Chau, Methvin Isaac, Babu Joseph, Radek Laufer, Gennady Poda, Michael Prakesch, David Uehling, Iain Watson, Brian Wilson, Tao Xin
  • HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1)
    Publication number: 20240343704
    Abstract: The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.
    Type: Application
    Filed: May 2, 2022
    Publication date: October 17, 2024
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Anh Chau, Methvin Isaac, Babu Joseph, Radek Laufer, Gennady Poda, Michael Prakesch, Pandiaraju Subramanian, David Uehling, Iain Watson, Brian Wilson, Tao Xin
  • SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1)
    Publication number: 20240317723
    Abstract: The present application relates to substituted amino aza-heteroaryl compounds of Formula (I) and substituted aza-heteroaryl compounds of Formula II or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.
    Type: Application
    Filed: May 2, 2022
    Publication date: September 26, 2024
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-Awar, Methvin Isaac, Babu Joseph, Radek Laufer, Ganna Posternak, Michael Prakesch, David Uehling, Iain Watson, Brian Wilson, Carlos Armando Zepeda-Velazquez, Anh Chau, Tao Xin
  • ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240092763
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 21, 2024
    Inventors: Rima Al-Awar, Liliana Attisano, Methvin Isaac, Yong Liu, David Smil, David Uehling, Jeff Wrana
  • THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240025887
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.
    Type: Application
    Filed: January 7, 2022
    Publication date: January 25, 2024
    Inventors: Rima Al-Awar, Liliana Attisano, Methvin Isaac, Yong Liu, David Smil, David Uehling, Jeff Wrana
  • SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20230219926
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 13, 2023
    Inventors: Rima AL-AWAR, Carlos Armando ZEPEDA-VELAZQUEZ, Gennady PODA, Methvin ISAAC, David UEHLING, Brian WILSON, Babu JOSEPH, Yong LIU, Pandiaraju SUBRAMANIAN, Ahmed MAMAI, Michael PRAKESCH, Julia Katheleen STILLE
  • Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
    Patent number: 11518764
    Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: December 6, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF
    Publication number: 20220267281
    Abstract: The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemical entities together for further use as medicaments and/or diagnostics.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 25, 2022
    Inventors: Ahmed MAMAI, Anh My CHAU, David Uehling
  • Compounds and methods for treating nematode infections
    Patent number: 11364234
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: June 21, 2022
    Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 11319299
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 3, 2022
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille
  • Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
    Patent number: 11242351
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 8, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 11174250
    Abstract: The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 16, 2021
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai
  • TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20210053978
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: February 25, 2021
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20200385371
    Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: September 6, 2018
    Publication date: December 10, 2020
    Applicant: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Methvin Isaac, Joseph Babu, Yong Liu, Ahmed Mamai, Gennady Poda, Pandiaraju Subramanian, David Uehling, Brian Wilson, Carlos Armando Zepeda-Velazquez
  • INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20200331921
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: February 6, 2019
    Publication date: October 22, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20190119264
    Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 25, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20190112290
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 18, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille